Mohamed Och
Psychiatry · Worcester, MANPI 1629098496
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by AbbVie at 37.8% of the total. Reporting peaked in 2019 at $13,317 and has fallen 94.9% since, to $675 in 2025. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 957 payments — averaging $46.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Otsuka America Pharmaceutical, Inc.$14K
- Johnson & Johnson$2K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $7K from 24 others
What the payments were for
- Speaking & faculty fees$23,62453%
- Travel & lodging$1,2993%
- Food & beverage$19,85144%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 228 | $16,983 |
| Otsuka America Pharmaceutical, Inc. | 152 | $14,210 |
| Johnson & Johnson | 60 | $1,902 |
| Alkermes, Inc. | 63 | $1,746 |
| Neurocrine Biosciences, Inc. | 56 | $1,376 |
| Teva Pharmaceuticals USA, Inc. | 46 | $1,258 |
| Vanda Pharmaceuticals Inc. | 45 | $1,150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $1,078 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $915 |
| Lundbeck LLC | 45 | $880 |
| Sunovion Pharmaceuticals Inc. | 65 | $757 |
| Axsome Therapeutics, Inc. | 11 | $466 |
| Bausch Health US, LLC | 42 | $451 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $351 |
| Neuronetics, Inc. | 2 | $250 |
| Merck | 14 | $246 |
| E.r. Squibb & Sons, L.L.C. | 3 | $227 |
| Avanir Pharmaceuticals, Inc. | 9 | $182 |
| Corium, LLC | 11 | $143 |
| Eisai Inc. | 4 | $78 |
| Almatica Pharma LLC | 2 | $51 |
| Arbor Pharmaceuticals, Inc. | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Pfizer | 2 | $27 |
| Braeburn Inc. | 1 | $19 |
| Orexo US, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$14,051
- REXULTI$11,582
- ARISTADA$1,429
- SPRAVATO$375
- ARISTADA INITIO$357
- CAPLYTA$323
- NEUROSTAR TMS THERAPY SYSTEM$250
- Auvelity$246
- INGREZZA$234
- AUSTEDO$228
- ABILIFY MAINTENA$226
- TRINTELLIX$176
- INVEGA SUSTENNA$147
- ABILIFY ASIMTUFII$122
How this compares
$44,938 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Worcester
- Amjad BahnassiWorcester$352K
- Mark SchlickmanWorcester$41K
- Anthony RothschildWorcester$34K
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Ernesto ZilberbergNorth Andover$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.